Novartis AG: Form 20-F for the period ended Dec 31, 2025
Filed with the SEC on Feb 4, 2026 and accepted by EDGAR at Feb 4, 2026, 06:45 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Cost of revenue | 12 months2025-01-01 to 2025-12-31 | $13.70bn | ifrs-full:CostOfSales |
| Gross profit | 12 months2025-01-01 to 2025-12-31 | $42.98bn | ifrs-full:GrossProfit |
| Operating income | 12 months2025-01-01 to 2025-12-31 | $17.64bn | ifrs-full:ProfitLossFromOperatingActivities |
| Income tax | 12 months2025-01-01 to 2025-12-31 | $2.38bn | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months2025-01-01 to 2025-12-31 | $13.98bn | ifrs-full:ProfitLossAttributableToOwnersOfParent |
| Diluted EPS | 12 months2025-01-01 to 2025-12-31 | $7.15 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months2025-01-01 to 2025-12-31 | $7.21 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months2025-01-01 to 2025-12-31 | $19.14bn | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months2025-01-01 to 2025-12-31 | $1.55bn | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | At period end2025-12-31 | $11.44bn | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2025-12-31 | $30.46bn | ifrs-full:CurrentAssets |
| Total assets | At period end2025-12-31 | $110.95bn | ifrs-full:Assets |
| Current liabilities | At period end2025-12-31 | $27.28bn | ifrs-full:CurrentLiabilities |
| Total liabilities | At period end2025-12-31 | $64.40bn | ifrs-full:Liabilities |
| Shareholders' equity | At period end2025-12-31 | $46.13bn | ifrs-full:EquityAttributableToOwnersOfParent |
| Shares outstanding | At period end2025-12-31 | 1,908,151,679 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001114448-26-000004. Last ingested by Listed: Oct 27, 2026, 17:27 ET. Listed shows no prices and gives no investment advice.